Methods and compositions for treating smith-magenis syndrome
AssigneeThe Regents of the University of California
InventorsYimin Zou, John Scott, Sonal Thakar
Life of this patent
Estimating the term…
Abstract
The present invention is based on the finding that subanesthetic doses of N-methyl-D-aspartate (NMDA) receptor antagonists alleviate social interaction deficits associated with behavioral disorders, such as Smith-Magenis Syndrome (SMS). The invention therefore provides methods and compositions for treating SMS. Also provided are methods of selecting NMDA receptor agonists useful in alleviating social interaction deficits associated with such behavioral disorders.
Claims5
A method for alleviating a social interaction deficit in a subject with a neurodegenerative disease or behavioral disorder, the neurodegenerative disease or behavioral disorder associated with lethal giant larvae (Lgl1) induced increase in synapses in a population of neurons in the subject's brain, comprising administering to the subject a subanesthetic amount of an N-methyl-D-aspartate (NMDA) receptor antagonist;
- wherein the NMDA receptor antagonist is selected from the group consisting of ketamine, memantine, dizocilpine (MK-801), dextromethorphan (DXM), phencyclidine (PCP), methoxetamine (MXE), and nitrous oxide (N2O);
- wherein the neurodegenerative disease or behavioral disorder is selected from the group consisting of Smith-Magenis Syndrome (SMS) and attention deficit hyperactivity disorder (ADHD).
A method of managing or treating a social interaction deficit in a subject with a neurodegenerative disease or behavioral disorder in a subject, comprising administering to the subject a subanesthetic amount of an N-methyl-D-aspartate (NMDA) receptor antagonist;
- wherein the NMDA receptor antagonist is selected from the group consisting of ketamine, memantine, dizocilpine (MK-801), dextromethorphan (DXM), phencyclidine (PCP), methoxetamine (MXE), and nitrous oxide (N2O);
- wherein the neurodegenerative disease or behavioral disorder is selected from the group consisting of Smith-Magenis Syndrome (SMS) and attention deficit hyperactivity disorder (ADHD).
Dependencies are inferred from the claim text.